利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.039 秒)

    WDRPUH epitope peptides and vaccines containing the same
    21.
    发明授权
    WDRPUH epitope peptides and vaccines containing the same 有权
    WDRPUH表位肽和含有它们的疫苗

    公开(公告)号：US08541546B2

    公开(公告)日：2013-09-24

    申请号：US13132891

    申请日：2009-12-03

    申请人： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： C07K4/12 ,  A61K38/04

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639

    摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

    摘要翻译： 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。

    MPHOSPH1 peptides and vaccines including the same
    23.
    发明授权
    MPHOSPH1 peptides and vaccines including the same 有权
    MPHOSPH1肽和疫苗包括相同

    公开(公告)号：US09458447B2

    公开(公告)日：2016-10-04

    申请号：US14131019

    申请日：2012-08-09

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Yusuke Nakamura

    IPC分类号： C07K7/00 ,  A61K38/10 ,  C12N9/00 ,  A61K39/00 ,  C07K14/47 ,  C12N9/14 ,  G01N33/50 ,  C12N5/0784 ,  C12N5/10 ,  G01N33/574 ,  A61K38/00

    CPC分类号： C12N9/93 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4738 ,  C12N5/0639 ,  C12N5/10 ,  C12N9/14 ,  C12N2502/1114 ,  C12Y306/04004 ,  G01N33/505 ,  G01N33/57407 ,  G01N2440/14

    摘要： As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.

    摘要翻译： 如本文更详细讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述提供的MPHOSPH1衍生的氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰形式保持必需的CTL诱导性 原始序列。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物或组合物。 本发明的肽，多核苷酸和药物或组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都具有特别的用途，包括例如膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠 癌症，胃癌，NSCLC，淋巴瘤，骨肉瘤，前列腺癌，肾癌和软组织肿瘤。

    WDHD1 peptides and vaccines including the same
    24.
    发明授权
    WDHD1 peptides and vaccines including the same 有权
    WDHD1肽和疫苗包括相同

    公开(公告)号：US09056890B2

    公开(公告)日：2015-06-16

    申请号：US13880442

    申请日：2011-10-20

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K38/00 ,  C07K7/06 ,  C07K14/47 ,  A61K39/00

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/47

    摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。

    SEMA5B peptides and vaccines including the same
    26.
    发明授权
    SEMA5B peptides and vaccines including the same 有权
    SEMA5B肽和疫苗包括它们

    公开(公告)号：US09187556B2

    公开(公告)日：2015-11-17

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K14/00 ,  C07K16/18 ,  C07K14/47 ,  G01N33/574 ,  A61K39/00 ,  A61K38/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME
    27.
    发明申请
    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    SEMA5B肽和疫苗，包括它们

    公开(公告)号：US20140178409A1

    公开(公告)日：2014-06-26

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

    MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME
    29.
    发明申请
    MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    MPHOSPH1肽和疫苗包括它们

    公开(公告)号：US20140154281A1

    公开(公告)日：2014-06-05

    申请号：US14131019

    申请日：2012-08-09

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Yusuke Nakamura

    IPC分类号： C12N9/00 ,  A61K39/00

    CPC分类号： C12N9/93 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4738 ,  C12N5/0639 ,  C12N5/10 ,  C12N9/14 ,  C12N2502/1114 ,  C12Y306/04004 ,  G01N33/505 ,  G01N33/57407 ,  G01N2440/14

    摘要： As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.

    摘要翻译： 如本文更详细讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述提供的MPHOSPH1衍生的氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰形式保持必需的CTL诱导性 原始序列。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物或组合物。 本发明的肽，多核苷酸和药物或组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都具有特别的用途，包括例如膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠 癌症，胃癌，NSCLC，淋巴瘤，骨肉瘤，前列腺癌，肾癌和软组织肿瘤。

    WDHD1 PEPTIDES AND VACCINES INCLUDING THE SAME
    30.
    发明申请
    WDHD1 PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    WDHD1肽和疫苗包括它们

    公开(公告)号：US20130309259A1

    公开(公告)日：2013-11-21

    申请号：US13880442

    申请日：2011-10-20

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： C07K7/06

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/47

    摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。